The Alliance for Longevity Initiatives (A4LI)

Longevity science and public demand are advancing rapidly, but real-world impact depends on policy that keeps pace with innovation. A4LI was founded as the first 501(c)(4) advocacy group to bridge this gap, championing policies that clear the path for researchers, founders, and investors alike.

Starting in 2027, A4LI will become a company membership organization, building a unified industry front on Capitol Hill. Membership empowers your organization to:

→ Influence National Policy: help shape the agenda on FDA pathway reform and research funding.
→ Join the Coalition: collaborate alongside fellow pioneers across biotech, clinical practice, and venture capital.
→ Accelerate the Timeline: drive policies that bring breakthrough therapies to the public faster.

Secure your seat at the table and help make healthy longevity a national priority: tinyurl.com/theA4LI

We can’t wait to be there!

Aging and Longevity Added to Focus Areas of FDA Regulatory Science

The @US_FDA’s Office of Regulatory and Emerging Science just released their Broad Agency Announcement for Fiscal Year 2027 and it includes aging and longevity as a focus area!

The agency is actively looking to fund external researchers, biotech innovators, and academic labs to solve the longevity field's biggest regulatory bottlenecks, including:

✅ Validating aging biomarkers with the goal of advancing candidates toward validated or reasonably likely surrogate endpoint status under the FDA-NIH BEST framework.
✅ Developing and modernizing clinical trial frameworks for aging related indications, including multimorbidity prevention frameworks and risk-enrichment strategies using validated aging biomarkers.
✅ Generating high-quality, longitudinal data-sets to assess the relationship between aging-related biomarkers (and its heterogeneity) and later clinical outcomes.

We want our longevity industry to succeed, so we must work together to build the tools, standards, and approaches needed for the FDA to evaluate the safety and efficacy of products that target the biology of aging.

Aging and longevity ARE public health initiatives and they perfectly align with the FDA’s 4 Public Health Pillars:

1️⃣ Innovation and Global Leadership
2️⃣ Advancing National Health Security
3️⃣ Increasing Access to Affordable Medicines & Medical Products
4️⃣ Preventing Chronic Disease and Promoting Wellness in America

So if you are building in this space, please apply! This is the regulatory and funding signal we have been waiting for. The deadline to submit for FY27 consideration is January 22, 2027.

🔗Explore the extramural R&D program and see how BAA funding works here: fda.gov/science-resear…

As populations age around the world, extending healthspan is becoming an increasingly important priority for governments and research institutions. Addressing age-related diseases and helping people remain healthier for longer will require advances in science, technology, and international collaboration.

In October, @ARPA_H sent a delegation to Japan for more than 20 engagements across seven cities, bringing together researchers, industry leaders, and government officials to explore opportunities for collaboration. Meetings with Japan's Cabinet Office, Ministry of Health, Labour and Welfare, Pharmaceuticals and Medical Devices Agency, and Japan Science and Technology Agency included discussions on regulatory science, biotechnology, and the growing need for longevity and healthspan interventions.

The visit builds on the U.S.-Japan Technology Prosperity Deal, advancing cooperation in health and biotechnology while opening new opportunities for research partnerships. ARPA-H is already pursuing international connections that could help programs like BoSS, which aims to make biologic medicines stable without refrigeration, benefit from Japanese expertise in biotechnology and distribution.

📖 Read the full recap here: arpa-h.gov/news-and-event…

At A4LI, we believe extending healthy human lifespan requires sustained investment in research and innovation. As aging becomes an increasingly important challenge for countries around the world, international collaboration can help accelerate scientific discoveries, advance new approaches to age-related diseases, and expand access to the breakthroughs that will allow more people to live longer, healthier lives.

Congratulations to the seven members of the Longevity Science Caucus who won re-election yesterday!

Rep. Gus Bilirakis (FL-12), Rep. Paul Tonko (NY-20), Rep. Ro Khanna (CA-17), Rep. Scott Peters (CA-50), Rep. Sam Liccardo (CA-16), Rep. Glenn Grothman (WI-6), and Rep. Lori Trahan (MA-3) will all return to Congress in January.

This bipartisan group has championed the idea that aging research is one of the best investments we can make in America's health and economy. We look forward to working with them in the 120th Congress to help more Americans live longer, healthier lives.